Matinas BioPharma Holdings Inc (MTNB) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.16 (+0.49%), Market cap $0.00B, 52-week low–high $0.49 ~ $2.36.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The
Financial statements, price targets, institutional (13F) holdings and related news for Matinas BioPharma Holdings Inc are updated in real time on BlackAll Trade.
Matinas BioPharma Holdings Inc trades at $0.16 (+0.49%). Real-time quotes and charts are available on BlackAll Trade.
Matinas BioPharma Holdings Inc has a market cap of about $0.00B.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC d